Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 23rd, 2026

Teleflex Incorporated (NYSE:TFX – Get Free Report) has earned an average rating of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $148.00.

A number of research firms have commented on TFX. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Wall Street Zen upgraded Teleflex from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Piper Sandler raised Teleflex from a “neutral” rating to an “overweight” rating and increased their price target for the company from $140.00 to $160.00 in a report on Monday, June 8th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday, May 8th.

Check Out Our Latest Report on Teleflex

Teleflex Price Performance Teleflex stock opened at $135.24 on Thursday. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The firm has a market capitalization of $5.99 billion, a price-to-earnings ratio of -5.93, a PEG ratio of 1.00 and a beta of 0.82. The company has a fifty day simple moving average of $130.79 and a 200-day simple moving average of $120.74. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82.

Teleflex (NYSE:TFX – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. The business had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company’s quarterly revenue was up 32.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities analysts anticipate that Teleflex will post 6.7 EPS for the current fiscal year.

Teleflex Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th were paid a $0.34 dividend. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is -5.96%.

Institutional Inflows and Outflows Institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC raised its stake in Teleflex by 1.1% during the first quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock worth $513,281,000 after purchasing an additional 45,199 shares during the period. AQR Capital Management LLC boosted its holdings in Teleflex by 478.1% in the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp boosted its holdings in Teleflex by 1.5% in the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock valued at $180,470,000 after purchasing an additional 22,111 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Teleflex by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after buying an additional 5,051 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Teleflex by 10.6% in the 4th quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company’s stock valued at $120,312,000 after buying an additional 94,679 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex (Get Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

Further Reading Five stocks we like better than Teleflex Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEVulcan Materials Company (NYSE:VMC) Receives Consensus Rating of “Moderate Buy” from Analysts

NEXT HEADLINE »Equinix, Inc. (NASDAQ:EQIX) Given Consensus Rating of “Moderate Buy” by Brokerages

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products, including short-term central venous catheters, arterial catheter products, and intraosseous vascular access solutions. “As healthcare sys.

Investors in Teleflex Incorporated (TFX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 17, 2026 $90.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for Teleflex, but what is the fundamental picture for the company? Currently, Teleflex is a Zacks Rank #3 (Hold) in the Medical - Instruments Industry that ranks in the Bottom 36% of our Zacks Industry Rank. Over the last 60 days, three analysts have increased their earnings estimate for the current quarter, while six have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from $1.69 per share to $1.28 per share in the same time period.

Given the way analysts feel about Teleflex right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

-

Calls on Board to Establish Strategic Review Sub-Committee with New Independent Directors to Oversee Process

NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today issued the following statement regarding the Company’s recent announcement:

“We welcome Teleflex's newfound openness to consider all strategic alternatives.

As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder representative and excluding Dr. Klasko, to work with its advisors to both engage with inbound approaches and solicit outbound interest — and report back to shareholders.

While we strongly disagree with the Board's description of our conversation with Dr. Klasko, we look forward to working with the Board to take appropriate next steps to maximize value at Teleflex.”

About Irenic
Irenic Capital Management, LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com.

More News From Irenic Capital Management, LP

Back to Newsroom

LOS ANGELES, April 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Teleflex Incorporated, (“Teleflex" or the "Company") (NYSE: TFX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. 

Investors are encouraged to CONTACT attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/teleflex-incorporated. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Teleflex’s stock price plummeted $16.52 per share, or 13.06%, to close at $110.01 per share on January 8, 2026, thereby injuring investors. This sharp market contraction was triggered by a January 8, 2026, announcement regarding a sudden and complete turnover in the Company’s highest level of corporate leadership. The primary driver of the valuation collapse was the disclosure that Liam Kelly had departed from his roles as Teleflex’s Chairman, President, and Chief Executive Officer.

The decline was further exacerbated by the "effective immediately" nature of the transition, which suggested an abrupt loss of institutional continuity and strategic oversight. The revelation that the Company was suddenly without its top executive across three core leadership functions led to an immediate loss of investor confidence and a rapid erosion of shareholder value as the market adjusted to the heightened uncertainty regarding Teleflex’s future direction and the potential for a leadership vacuum.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

On April 21, 2026, Teleflex Inc TFX shares fell 5.5% today to a current price of $124.75. This decline comes amid a 52-week trading range of $100.18 to $138.93. The stock has seen mixed performance recently, with a year-to-date increase of 2.5% but a 1-year decline of 2.3%.

GF Value™ verdict: $124.75 vs $183.22, 31.9% undervaluedGF Score™: 75/100, indicating above-average potentialMost notable signal: No insider transactions in the last 3 months Is TFX Overvalued or Undervalued? With a current price of $124.75 and a GF Value™ of $183.22, Teleflex Inc appears significantly undervalued, presenting a margin of safety of 31.9%. This suggests that the stock may offer an attractive opportunity for potential investors who believe in its long-term growth prospects. The GF Valuation label classifies TFX as significantly undervalued, indicating that the current market price does not reflect the company's intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the undervaluation presents an opportunity, investors should exercise caution as the company's predictability rating is only 1 star, suggesting potential volatility and uncertainty in future performance. The lack of insider transactions in recent months may also point to a cautious sentiment among company executives regarding the stock's short-term prospects.

How Does TFX's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 18.6x 33.0x Currently, Teleflex Inc's forward P/E ratio of 18.6x is significantly lower than its 5-year median P/E of 33.0x, indicating that the stock is trading below its historical valuation. This P/E analysis aligns with the GF Value™ verdict, reinforcing the view that TFX is undervalued at its current price.

What Does TFX's GF Score™ Tell Us? Metric Rating GF Score™ 75/100 Financial Strength 5/10 Profitability 6/10 Growth 5/10 Valuation 8/10 Momentum 4/10 The GF Score™ of 75/100 indicates that Teleflex Inc has above-average potential for long-term returns based on its financial health and operational performance. The strongest area is its Valuation rank at 8/10, suggesting the stock is attractively priced relative to its underlying value. However, the weakest area is the Momentum rank at 4/10, indicating potential challenges in maintaining upward price trends in the short term.

What Are Insiders Doing with TFX Stock? In the last three months, there have been no insider transactions reported for Teleflex Inc, indicating a lack of buying or selling activity among executives and board members. This lack of insider movement may suggest a cautious approach from management regarding the stock's near-term performance, reflecting uncertainty in the broader market or company-specific developments.

What This Means for Investors Based on the analysis of GF Value™, Teleflex Inc is currently undervalued. The significant difference between the current share price and the estimated fair value presents a potential opportunity for investors looking to capitalize on future growth. However, potential investors should remain aware of the company's financial strength and predictability metrics.

For the complete analysis, visit the Teleflex Inc TFX stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is TFX's GF Score™?

TFX has a GF Score™ of 75/100, indicating above-average potential for long-term returns based on key financial metrics.

Is TFX overvalued or undervalued?

TFX is currently undervalued with a GF Value™ of $183.22 compared to its current price of $124.75, showing significant upside potential.

What is TFX's P/E ratio?

TFX's forward P/E ratio is 18.6x, which is well below its historical 5-year median P/E of 33.0x, suggesting it is trading at a lower valuation compared to its past performance.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Proven Industry Leader to Guide Company’s Next Chapter of Growth and Value Creation

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex’s Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO.

Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc, where he held a number of senior leadership roles over nearly two decades, most recently serving as SVP and President, Coronary & Renal Denervation, and SVP and President, Aortic, Peripheral and Venous. In these positions, he oversaw significant growth and global expansion of multi-billion dollar revenue operating units, including the successful launch of key innovations and acquisitions.

“We’re thrilled to welcome Jason to Teleflex. Following the completion of the divestitures, Teleflex will be a fundamentally transformed company, with a portfolio focused on our core interventional, critical care and high acuity hospital markets,” said Dr. Stephen Klasko, Teleflex’s Chairman of the Board. “Jason’s medical technology expertise is closely aligned with our focused product portfolio, and his track record of driving growth, advancing product innovations and expanding global markets make him an ideal candidate to lead Teleflex’s go-forward strategy. With attractive, high-growth end markets, what will be a significantly enhanced capital structure from our intended $1 billion share buyback and $800 million debt paydown following the close of the sale transactions and an experienced and driven leadership team, we believe Teleflex will be an incredibly compelling growth story.”

“It’s an honor for me to join Teleflex at such an important inflection point and to help lead the Company into its next phase of growth,” said Mr. Weidman. “Having spent my entire career in the medical technology industry, I see a clear opportunity for Teleflex to build on its strong foundation and commitment to innovation, further shaping the future of healthcare while advancing our purpose of improving the health and quality of people’s lives.”

Dr. Klasko added, “I also want to thank Stuart for his leadership over the past four months. The Board and I are grateful for his contributions and value his continued insights and guidance as a member of our Board.”

About Jason Weidman

Mr. Weidman brings over 25 years of experience in the medical device industry. He held key leadership roles at Medtronic from 2006 – 2026, including his most recent roles of SVP and President, Coronary & Renal Denervation and SVP and President, Aortic, Peripheral and Venous, where he spearheaded strategic product innovations and market development initiatives in coronary and peripheral vascular markets. Prior to Medtronic, Mr. Weidman held roles at Thoratec Corporation.

Mr. Weidman received an MBA in Health Care Management from the Wharton School at the University of Pennsylvania, an MS in Mechanical Engineering with a concentration in Biomechanics from Stanford University and a BSE in Mechanical Engineering from the University of Michigan.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026.

First quarter 2026 continuing operations financial summary1

Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1

Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%2 Maintaining GAAP EPS from continuing operations guidance range of $2.90 to $3.20 Maintaining Adjusted diluted EPS from continuing operations guidance range to $6.25 to $6.55 Includes full year impact of stranded costs estimated to be $90 million Excludes expected benefits from transition services (“TS”) and manufacturing services (“MS”) agreements that come into effect upon closing of Strategic Divestitures, which we anticipate will fully offset stranded costs on an annualized basis Excludes impact of repurchases under previously announced $1 billion share repurchase program and expected debt paydown of ~$800 million primarily funded by closing of Strategic Divestitures "Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer. "We delivered a strong start to the year, with 5.1% pro forma adjusted constant currency revenue growth year-over-year, and we continue to expect our two strategic divestitures to close in the second half of 2026. We remain committed to using the majority of the net proceeds from the sales transactions to return capital to shareholders through our $1 billion share repurchase authorization, while also reducing debt by $800 million to enhance financial flexibility and support future growth. These actions are advancing our strategy to optimize our portfolio, strengthen Teleflex's position as a focused medical technologies leader and drive long-term value creation."

Mr. Randle continued, “We recently announced the appointment of Jason Weidman as President and Chief Executive Officer, effective June 8, 2026. His deep medical technology expertise and proven track record of driving growth and innovation make him well suited to lead Teleflex into its next chapter and capitalize on the opportunities ahead. Additionally, consistent with our commitment to strong governance and creating shareholder value, we announced several actions in April, including the nomination of Michael J. Tokich to our Board of Directors, the initiation of opportunistic open-market share repurchases in the second quarter and our intent to establish a new Growth and Operating Committee of the Board.”

(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".

(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment and (b) the impact of foreign exchange.

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three months ended March 31, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.

Three Months Ended

March 31, 2026

March 30, 2025

% Increase

/

(Decrease)

Reported

revenue

Adjustment

Pro Forma

Adjusted

Revenue

Reported

revenue

Adjustment

Pro Forma

Adjusted

Revenue

Reported

Revenue

Growth

Currency

Impact

Adjustment

impact

Pro Forma

Adjusted

Constant

Currency

Revenue

Growth

Vascular Access

$236.8

$—

$236.8

$219.1

$—

$219.1

8.1%

3.3%

—%

4.8%

Interventional1

204.7

—

204.7

100.2

92.6

192.8

104.4%

3.1%

98.3%

3.0%

Surgical2

106.8

—

106.8

95.0

(0.5)

94.5

12.4%

3.1%

(0.6)%

9.9%

Consolidated1

$548.3

$—

$548.3

$414.3

$92.1

$506.4

32.3%

3.2%

24.0%

5.1%

OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS

Depreciation expense, amortization of intangible assets and deferred financing charges for the three months ended March 31, 2026 totaled $55.2 million compared to $39.5 million for the prior year period. Total cash, cash equivalents and restricted cash equivalents at March 31, 2026 were $329.6 million compared to $402.7 million at December 31, 2025. Net accounts receivable at March 31, 2026 were $365.5 million compared to $345.6 million at December 31, 2025. Inventories at March 31, 2026 were $380.9 million compared to $404.4 million at December 31, 2025. 2026 CONTINUING OPERATIONS OUTLOOK

On a GAAP basis, the Company continues to expect full year 2026 revenue growth from continuing operations of 14.40% to 15.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company is maintaining full year 2026 revenue growth from continuing operations of 4.50% to 5.50%.

The Company maintained its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.90 to $3.20. The Company continues to expect full year 2026 adjusted diluted earnings per share from continuing operations of $6.25 to $6.55.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation

2025

2026 Guidance

Low

High

GAAP revenue

$1,992.7

$2,280

$2,300

Vascular Intervention pro forma adjustment

$199.0

—

—

Discontinued product adjustment

$(14.3)

—

—

Italian payback measure adjustment

$(9.0)

—

—

Pro forma adjusted revenue

$2,168.4

$2,280

$2,300

Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation

Low

High

Forecasted 2026 GAAP revenue growth

14.4%

15.4%

Vascular Intervention pro forma adjustment

10.0%

10.0%

Discontinued product adjustment

(0.7)%

(0.7)%

Italian payback measure adjustment

(0.5)%

(0.5)%

Base year adjustment (GAAP versus pro forma adjusted)

0.4%

0.4%

Estimated impact of foreign currency exchange rate fluctuations

0.7%

0.7%

Forecasted 2026 pro forma adjusted constant currency revenue growth

4.5%

5.5%

Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

Low

High

Forecasted GAAP diluted earnings per share from continuing operations

$2.90

$3.20

Restructuring and optimization items, net of tax

$0.90

$0.90

Acquisition, integration and divestiture related items, net of tax

$0.61

$0.61

Other items, net of tax

$(0.65)

$(0.65)

ERP implementation, net of tax

$0.30

$0.30

MDR, net of tax

$0.02

$0.02

Intangible amortization expense, net of tax

$2.17

$2.17

Forecasted adjusted diluted earnings per share from continuing operations, net of tax

$6.25

$6.55

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's first quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on May 7, 2026.

An audio replay of the investor call will be available beginning at 11:00 am ET on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; and (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.

Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations for the three months ended March 31, 2026 and the comparable prior year period.

Q1 2026

Q1 2025

Vascular

236.8

219.1

Interventional

204.7

100.2

Surgical

106.8

95.0

GAAP revenue

548.3

414.3

Interventional - Vascular Intervention

—

95.2

Interventional - Discontinued Products

—

(2.6)

Surgical - Discontinued Products

—

(0.5)

Pro forma adjusted revenue

$548.3

$506.4

Vascular

236.8

219.1

Interventional

204.7

192.8

Surgical

106.8

94.5

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended March 31, 2026

Revenue

Gross

margin

SG&A (1)

R&D (1)

Operating

margin (2)

(Loss) Income

before income

taxes

Income tax

expense

Effective

income tax

rate

Diluted (loss)

earnings per

share from

continuing

operations

GAAP Basis - Continuing Operations

$548.3

56.1%

41.2%

8.1%

3.7%

$(3.8)

$1.0

(26.4)%

$(0.11)

Adjustments

Restructuring and optimization charges (A)

—

0.6

(1.4)

—

5.0

28.0

4.4

0.54

Acquisition, integration and divestiture related items (B)

—

1.4

(1.0)

—

2.4

13.0

3.1

0.22

ERP implementation

—

—

(0.7)

—

0.7

3.9

0.7

0.07

MDR

—

—

—

(0.1)

0.1

0.4

—

0.01

Intangible amortization expense

—

3.3

(2.9)

—

6.2

33.9

4.6

0.66

Adjustments total

—

5.3

(6.0)

(0.1)

14.4

79.2

12.8

1.50

Adjusted basis

$548.3

61.4%

35.2%

8.0%

18.1%

$75.4

$13.8

18.3%

$1.39

Three Months Ended March 30, 2025

Revenue

Gross

margin

SG&A (1)

R&D (1)

Operating

margin (2)

Income before

income taxes

Income tax

expense

Effective

income tax

rate

Diluted

earnings per

share from

continuing

operations

GAAP Basis - Continuing Operations

$414.3

61.7%

36.9%

6.1%

18.3%

$58.8

$6.4

10.9%

$1.14

Adjustments

Restructuring and optimization charges (A)

—

1.1

—

—

1.5

6.0

1.0

0.11

Acquisition, integration and divestiture related items (B)

—

—

4.4

—

(4.4)

(18.1)

0.8

(0.42)

ERP implementation

—

—

(1.4)

—

1.4

5.9

1.0

0.11

MDR

—

—

—

(0.2)

0.2

0.7

—

0.02

Intangible amortization expense

—

3.3

(2.9)

—

6.2

25.6

3.1

0.49

Tax adjustments

—

—

—

—

—

—

0.7

(0.01)

Adjustments total

—

4.4

0.1

(0.2)

4.9

20.1

6.6

0.30

Adjusted basis

$414.3

66.1%

37.0%

5.9%

23.2%

$78.9

$13.0

16.4%

$1.44

Notes:

(1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

ABOUT TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, forecasted 2026 GAAP, pro forma adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results; statements about the pending Strategic Divestitures, the expected timetable for completing the Strategic Divestitures and the future financial and operating performance of the company following completion of the Strategic Divestitures; statements regarding our intended use of the net proceeds from the Strategic Divestitures; and statements regarding our ability to drive durable performance and long-term value for shareholders. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

Three Months Ended

March 31, 2026

March 30, 2025

(Dollars and shares in thousands, except per share)

Net revenues

$

548,262

$

414,258

Cost of goods sold

240,836

158,827

Gross profit

307,426

255,431

Selling, general and administrative expenses

226,012

152,914

Research and development expenses

44,386

25,295

Restructuring charges, separation costs and impairment charges

16,845

1,422

Income from continuing operations before interest and taxes

20,183

75,800

Interest expense

25,718

18,537

Interest income

(1,708

)

(1,488

)

(Loss) income from continuing operations before taxes

(3,827

)

58,751

Taxes on income from continuing operations

1,011

6,417

(Loss) income from continuing operations

(4,838

)

52,334

Operating (loss) income from discontinued operations

(2,643

)

50,060

Taxes on operating income from discontinued operations

673

7,392

(Loss) income from discontinued operations

(3,316

)

42,668

Net (loss) income

$

(8,154

)

$

95,002

Earnings per share:

Basic:

(Loss) Income from continuing operations

$

(0.11

)

$

1.14

(Loss) Income from discontinued operations

(0.07

)

0.94

Net (loss) income

$

(0.18

)

$

2.08

Diluted:

(Loss) Income from continuing operations

$

(0.11

)

$

1.14

(Loss) Income from discontinued operations

(0.07

)

0.93

Net (loss) income

$

(0.18

)

$

2.07

Weighted average common shares outstanding

Basic

44,257

45,782

Diluted

44,257

45,926

TELEFLEX INCORPORATED

CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, 2026

December 31, 2025

(Dollars in thousands)

ASSETS

Current assets

Cash and cash equivalents

$

309,411

$

378,564

Accounts receivable, net

365,526

345,583

Inventories

380,861

404,395

Prepaid expenses and other current assets

149,808

150,678

Prepaid taxes

16,793

19,566

Current assets of discontinued operations

637,271

639,552

Total current assets

1,859,670

1,938,338

Property, plant and equipment, net

476,955

498,281

Operating lease assets

84,912

91,817

Goodwill

2,297,447

2,305,050

Intangibles assets, net

1,485,885

1,524,150

Deferred tax assets

12,206

12,593

Other assets

113,557

112,984

Non-current assets of discontinued operations

452,370

464,026

Total assets

6,783,002

6,947,239

LIABILITIES AND EQUITY

Current liabilities

Current borrowings

$

103,125

$

100,000

Accounts payable

143,627

130,201

Accrued expenses

118,423

117,350

Payroll and benefit-related liabilities

103,345

124,769

Accrued interest

16,478

5,404

Income taxes payable

11,824

18,787

Other current liabilities

103,929

137,195

Current liabilities of discontinued operations

127,298

128,320

Total current liabilities

728,049

762,026

Long-term borrowings

2,514,268

2,541,449

Deferred tax liabilities

169,429

183,749

Noncurrent liability for uncertain tax positions

3,831

3,536

Noncurrent operating lease liabilities

68,320

84,210

Other liabilities

162,507

194,532

Non-current liabilities of discontinued operations

52,162

52,969

Total liabilities

3,698,566

3,822,471

Commitments and contingencies

Total shareholders' equity

3,084,436

3,124,768

Total liabilities and shareholders' equity

$

6,783,002

$

6,947,239

  TELEFLEX INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Three Months Ended

March 31, 2026

March 30, 2025

(Dollars in thousands)

Cash flows from operating activities of continuing operations:

Net (loss) income

$

(8,154

)

$

95,002

Adjustments to reconcile net income to net cash provided by operating activities:

(Income) loss from discontinued operations

3,316

(42,668

)

Depreciation expense

19,853

13,037

Intangible asset amortization expense

33,890

25,583

Deferred financing costs and debt discount amortization expense

1,481

851

Changes in contingent consideration

(2,632

)

(1,795

)

Stock-based compensation

6,742

6,630

Gain on non-designated foreign currency forward contracts

—

(23,268

)

Deferred income taxes, net

(12,710

)

(108

)

Interest benefit on swaps designated as net investment hedges

(8,305

)

(4,239

)

Other

3,558

762

Changes in assets and liabilities, net of effects of acquisitions and disposals:

Accounts receivable

(25,005

)

(10,939

)

Inventories

16,473

(3,474

)

Prepaid expenses and other assets

3,432

(12,724

)

Accounts payable, accrued expenses and other liabilities

8,197

(17,488

)

Income taxes receivable and payable, net

6,526

2,562

Net cash provided by operating activities from continuing operations

46,662

27,724

Cash flows from investing activities of continuing operations:

Expenditures for property, plant and equipment

(18,791

)

(24,132

)

Payments for businesses and intangibles acquired, net of cash acquired

—

(90

)

Insurance settlement proceeds

—

6,307

Net payments on swaps designated as net investment hedges

(53,494

)

—

Purchase of investments

(2,500

)

(5,000

)

Net cash used in investing activities from continuing operations

(74,785

)

(22,915

)

Cash flows from financing activities of continuing operations:

Proceeds from new borrowings

—

300,000

Reduction in borrowings

(25,250

)

(49,125

)

Repurchase of common stock

—

(300,000

)

Net (payments) proceeds from share based compensation plans and related tax impacts

(4,627

)

7,348

Payments for contingent consideration

(58

)

(56

)

Dividends paid

(15,050

)

(15,191

)

Debt extinguishment, issuance and amendment fees

—

(2,500

)

Net cash used in financing activities from continuing operations

(44,985

)

(59,524

)

Cash flows from discontinued operations:

Net cash provided by operating activities

2,362

45,370

Net cash used in investing activities

(9,214

)

(5,879

)

Net cash used in discontinued operations

(6,852

)

39,491

Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents

(4,890

)

5,052

Net increase in cash, cash equivalents and restricted cash equivalents

(84,850

)

(10,172

)

Cash, cash equivalents and restricted cash equivalents at the beginning of the period

453,848

327,650

Less: Cash, cash equivalents and restricted cash of discontinued operations

(39,448

)

(35,397

)

Cash, cash equivalents and restricted cash equivalents at the end of the period

$

329,550

$

282,081

For the quarter ended March 2026, Teleflex (TFX - Free Report) reported revenue of $548.26 million, down 21.8% over the same period last year. EPS came in at $1.39, compared to $2.91 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $533.74 million, representing a surprise of +2.72%. The company delivered an EPS surprise of +14.75%, with the consensus EPS estimate being $1.21.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Surgical: $106.8 million compared to the $102.19 million average estimate based on 11 analysts. The reported number represents a change of +1% year over year.Revenues- Interventional: $204.7 million compared to the $210.39 million average estimate based on eight analysts.Revenues- Vascular: $236.8 million compared to the $223.03 million average estimate based on eight analysts.View all Key Company Metrics for Teleflex here>>>

Shares of Teleflex have returned +3.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways Teleflex Q1 revenues rose 32.3% to $548.3M, topping estimates on strong segment growth.TFX gross margin fell 559 bps to 56.1% as the cost of goods sold jumped 51.6% year over year.Teleflex reaffirmed 2026 revenue and adjusted EPS guidance despite margin pressure. Teleflex Inc. (TFX - Free Report) posted first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of $1.39, down 3.5% from the year-ago quarter’s figure. However, the metric topped the Zacks Consensus Estimate by 14.75%.

GAAP loss per share was 11 cents compared to EPS of $1.14 in the prior-year period.

TFX’s RevenuesFirst-quarter revenues from continuing operations were $548.26 million, up 32.3% year over year and surpassed the Zacks Consensus Estimate by 2.72%.

On a pro forma adjusted constant currency basis — which includes prior-year revenues from the acquired Vascular Intervention business, and excludes foreign exchange and revenues from products discontinued after the 2025 strategic realignment — revenues rose 5.1% in the quarter.

Since the announcement on May 7, shares of the company have fallen 2% to close the session at $131.56 yesterday.

Segmental Analysis of TFX’s Q1 RevenuesThe Vascular segment recorded pro forma adjusted revenues of $236.8 million, up 8.1% on a reported basis and 4.8% on a pro forma adjusted constant currency basis. Growth was mainly driven by hemostatic products in the central venous and other access portfolio.

The Interventional business registered pro forma adjusted revenues of $204.7 million, up 104.4% on a reported basis and 3% on a pro forma adjusted constant currency basis. Performance was led by the intraosseous, right heart catheters and complex catheters.

The Surgical segment recorded pro forma adjusted revenues of $106.8 million, up 12.4% on a reported basis and up 9.9% on a pro forma adjusted constant currency basis. Growth was led by the strong performance in the ligation clip and some timing of orders in the instrument portfolio.

TFX’s Q1 Margin PerformanceThe gross profit was $307.4 million, up 20.4% year over year. The gross margin contracted 559 basis points (bps) to 56.1% due to a 51.6% rise in the cost of goods sold.

Overall, the adjusted operating profit was $37 million, down 52.1% year over year. The adjusted operating margin contracted 1189 bps to 6.8%.

TFX’s Liquidity PositionTeleflex exited the first quarter of 2026 with cash and cash equivalents of $309.4 million compared with $378.6 million at the end of 2025.

Net cash flow provided by operating activities from continuing operations was $46.7 million compared with $27.7 million in the year-ago period.

Teleflex’s 2026 GuidanceOn a GAAP basis, the company continues to expect full-year 2026 revenue growth from continuing operations of 14.4% to 15.4%. Pro forma adjusted constant currency revenue growth for 2026 is also unchanged at 4.50% to 5.50%.

The Zacks Consensus Estimate for total revenues is pegged at $2.29 billion, indicating a 22.9% decline.

Adjusted EPS from continuing operations is projected in the range of $6.25-$6.55, also unchanged from the previous forecast. The Zacks Consensus Estimate for the metric is pegged at $8.41.

Our TakeTeleflex delivered better-than-expected earnings and revenues in the first quarter of 2026. The company demonstrated strong execution and also, to some extent, benefited from the timing of orders in its surgical instrument portfolio. Within Interventional, Teleflex continues to integrate the Vascular Intervention business, which closed early in the third quarter of 2025. The company is also making progress on its strategic priorities, which include driving durable performance and building a clear financial profile through improved margins, lower interest expense and stronger adjusted EPS over time.

Meanwhile, the strategic divestitures of the acute care, interventional urology and OEM businesses are expected to close in the second half of 2026.

TFX’s Zacks Rank and Key PicksTeleflex currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .

BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Labcorp, carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.

LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.

In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026.

Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment1 with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.2

CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System*

At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezūm™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.1

The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.1

Key study endpoints of the study:

Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezūm™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively1 Early patient experience was better for the UroLift™ System patients compared to Rezūm™ patients1 UroLift™ System and Rezūm™ subjects had similar durability through 12 months1 Patients’ sexual function† was preserved through 12 months with the UroLift™ System1 “What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y.

Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity*

At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.2

Key endpoints of the study:

Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm2 Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control2 These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.2

“The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.” 2

“These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.”

About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,3 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.4,5 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.†6-7 A study conducted over five years showed a low retreatment rate of about 2 to 3 percent per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.8 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.9 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.10 Learn more at www.UroLift.com.

UroLift System Important Safety Information
The UroLift™ System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 45 years or older with prostates ≤100 cc. Contraindicated in men with current gross hematuria, urinary tract infection, urinary incontinence due to incompetent sphincter, and urethral conditions that prevent device insertion. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. Visit urolift.com.

About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.11 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).12

Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.13,14

Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy11 and is cleared for rectal spacing in the United States, Australia, and Europe.15 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters.

Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, the intent is to reduce the radiation dose delivered to the anterior rectum. It is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.

It should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.

Potential complications include but are not limited to: pain associated with the injection; needle penetration or injection of Barrigel rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. Contraindicated in prostate cancer patients with clinical stage T4 disease. Individual results may vary. Visit barrigel.com.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

About Interventional Urology
The Interventional Urology Business Unit is leading in prostate health by advancing clinical evidence, elevating education, and supporting physicians and patients. Our portfolio includes Barrigel™ rectal spacer for men seeking to reduce rectal side effects associated with prostate cancer radiation therapy, the UroLift™ System for men suffering from BPH symptoms, and Deflux™ injectable gel for children with grades II-V vesicoureteral reflux (VUR).

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Barrigel, Deflux, and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2026 Teleflex Incorporated. All rights reserved. APM1495A

*Studies sponsored by Teleflex.

**Drs. Chughtai and King are paid consultants of Teleflex

†No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study

References

Chughtai et al. J Urol 2026 King M, Chao M et al. Prospective Randomized Controlled Trial of Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: 3-Year Results. Presented at: European Society for Radiotherapy and Oncology 2026 Annual Congress; May 2026; Stockholm, Sweden. Proffered Paper 3623. Shore, Can J Urol 2014 Rukstalis, Prostate Cancer Prostatic Dis 2018 UroLift™ System Instructions for Use AUA BPH Guidelines 2003, 2020 McVary, Urology 2019 Roehrborn, Can J Urol 2017 Roehrborn, J Urol 2013 Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology. Mariados NF, Orio PF III, King M et al. JAMA Oncol (2023)*,** Barrigel Injectable Gel Instructions for Use (2022) Svatos M, Chell E, Low DA et al. Med Phys (2024)*,** Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Data on file Teleflex. 2025

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing.

The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness.

Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”).

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the terms of and completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the “Notes”) at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions.

The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness.

Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the “2027 Notes”).

The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the United States only to investors who are reasonably believed to be “qualified institutional buyers,” as that term is defined in Rule 144A under the Securities Act, or to certain non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act. The Notes and the related guarantees have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not an offer to purchase or a solicitation of an offer to sell with respect to the 2027 Notes.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. Teleflex is the home of Arrow®, Barrigel®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about the completion of the offering of the Notes, the anticipated use of the net proceeds from the offering and the redemption of the outstanding 2027 Notes. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on February 27, 2026 and our Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, which can be obtained on the SEC’s website at http://www.sec.gov. We undertake no obligation to publicly update or revise any forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.